Skip to content

Study · Not a test of the peptide alone · 2011

1 result

mu-Opioid receptor stimulation in the nucleus accumbens elevates fatty tastant intake by increasing palatability and suppressing satiety signals.

Katsuura Y, Heckmann JA, Taha SA

American journal of physiology. Regulatory, integrative and comparative physiology4 May 2011Cited by 46 (Europe PMC)

PMID21543633 (opens in a new tab)PMCIDPMC3129872 (opens in a new tab)DOI10.1152/ajpregu.00406.2010 (opens in a new tab)PepBankPUB-21543633
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome

    In rats, stimulation of mu-opioid receptors in the nucleus accumbens core reversed the suppression of intake that third-ventricle MTII caused.

    In plain wordsIn rats, stimulating opioid receptors in one brain region reversed the reduced eating that MTII caused.

    Peptide
    Melanotan II
    Outcome
    IncreaseReversal of MTII-induced intake suppression by MOR stimulation
    Study

    ratn: not reported in source

    nucleus accumbens core MOR stimulation
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Suppression of intake caused by MTII was reversed by MOR stimulation.
    1 context sentence
    Summary · context
    In experiment 3, we determined whether MOR activation in the NAcc core could attenuate satiety-related signaling caused by infusion of the melanocortin agonist MTII into the third ventricle.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.